About Us

Arch Oncology

Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.

We are advancing our lead therapy AO-176 into clinical development for the treatment of solid tumors. Our leadership team has successfully developed new drugs for patients before and we are backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, and 3x5 Partners.

Our leadership team has successfully developed new drugs for patients before